Research Topics
| Thomas GilesSummaryCountry: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Comparative efficacy of aliskiren/valsartan vs valsartan in nocturnal dipper and nondipper hypertensive patients: a pooled analysisThomas D Giles
Heart and Vascular Institute, Tulane University School of Medicine, New Orleans, LA 70005, USA
J Clin Hypertens (Greenwich) 14:299-306. 2012..Although the addition of aliskiren to valsartan did not significantly alter dipper status, our data suggest an increased contribution of the renin-angiotensin-aldosterone system to the nondipper status of hypertensive patients...
Impaired vasodilation in the pathogenesis of hypertension: focus on nitric oxide, endothelial-derived hyperpolarizing factors, and prostaglandinsThomas D Giles
Heart and Vascular Institute, Tulane University Medical Center, New Orleans, LA, USA
J Clin Hypertens (Greenwich) 14:198-205. 2012..Possible pharmacological interventions to restore normal function are suggested...
Effects of thiazolidinediones on blood pressureThomas D Giles
Section of Cardiology, Department of Medicine, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, LA 70112, USA
Curr Hypertens Rep 9:332-7. 2007..A significant proportion of patients with type 2 diabetes mellitus and BP mildly above target range might be successfully treated for both processes with a single drug...
Definition and classification of hypertension: an updateThomas D Giles
Tulane University School of Medicine, Metairie, LA 7005, USA
J Clin Hypertens (Greenwich) 11:611-4. 2009..This paper discusses the logic underlying the refinements in the definition of hypertension...
Comparison of pioglitazone vs glyburide in early heart failure: insights from a randomized controlled study of patients with type 2 diabetes and mild cardiac diseaseThomas D Giles
Tulane University School of Medicine, New Orleans, LA, USA
Congest Heart Fail 16:111-7. 2010..2% vs 12.8%), and weight gain (2.56+/-4.62 kg vs 0.86+/-3.85 kg) were observed than with glyburide...
The role of vasodilating beta-blockers in patients with complicated hypertension: focus on nebivololThomas D Giles
Department of Medicine, Tulane University School of Medicine, New Orleans, Louisiana, USA
Am J Med 123:S16-20. 2010..g., elderly patients, African American patients), a vasodilating beta-blocker may be a particularly appropriate choice for these patient groups...
Ethnic/racial variations in blood pressure awareness, treatment, and controlThomas Giles
Tulane University School of Medicine, New Orleans, LA, USA
J Clin Hypertens (Greenwich) 9:345-54. 2007..Effective interventions targeting Mexican Americans and blacks as well as whites are essential to improving hypertension management...
Circadian rhythm of blood pressure and the relation to cardiovascular eventsThomas D Giles
Louisiana State University Health Sciences Center, New Orleans, 70112, USA
J Hypertens Suppl 24:S11-6. 2006....
The Trial of Preventing Hypertension (TROPHY) as seen through the eyes of the Hypertension Writing Group's expanded definition of hypertensionThomas D Giles
Department of Medicine, Louisiana State University Medical Center, New Orleans, LA 70112, USA
J Clin Hypertens (Greenwich) 8:441-3. 2006
Aspects of nitric oxide in health and disease: a focus on hypertension and cardiovascular diseaseThomas D Giles
Division of Cardiology, Tulane University School of Medicine, New Orleans, LA, USA
J Clin Hypertens (Greenwich) 8:2-16. 2006..Other cardiovascular therapies that may improve NO bioactivity include statins, l-arginine, and nonpharmacologic approaches such as exercise and dietary changes...
Should we redefine hypertension?Thomas D Giles
Department of Medicine, Tulane University School of Medicine, 109 Holly Drive, Metairie, LA 70005, USA
Curr Cardiol Rep 8:395-8. 2006..This definition of hypertension will permit physicians to treat patients with the goal of reducing global risk for myocardial infarction, stroke, and chronic kidney disease...
Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertensionThomas D Giles
Tulane University School of Medicine, New Orleans, LA 70005, USA
J Clin Hypertens (Greenwich) 9:187-95. 2007..001). Olmesartan did not reduce mean SeDBP significantly compared with valsartan, although more patients attained blood pressure goal with olmesartan (P=.031). At week 12, all agents lowered blood pressure equivalently...
The role of ambulatory blood pressure monitoring compared with clinic and home blood pressure measures in evaluating moderate versus intensive treatment of hypertension with amlodipine/valsartan for patients uncontrolled on angiotensin receptor blocker moThomas D Giles
Tulane University School of Medicine, New Orleans, Louisiana, USA
Blood Press Monit 16:87-95. 2011..Home BP was measured on the morning of clinic visits to minimize differences that timing might have on home versus office BP measures...
Assessment of global risk: a foundation for a new, better definition of hypertensionThomas D Giles
Tulane University School of Medicine, New Orleans, LA, USA
J Clin Hypertens (Greenwich) 8:5-14; quiz 39. 2006..This revision of the definition of hypertension and the need to assess BP levels in the context of global cardiovascular risk should lead to earlier detection of at-risk patients...
The role of nitric oxide in improving endothelial function and cardiovascular health: focus on nebivololGeorge L Bakris
Hypertensive Diseases Unit, Department of Medicine, University of Chicago Medical Center, Chicago, Illinois, USA
Am J Med 123:S2-8. 2010....
Stimulus response of blood pressure in black and white young individuals helps explain racial divergence in adult cardiovascular disease: the Bogalusa Heart StudyGerald S Berenson
Tulane Center for Cardiovascular Health, New Orleans, LA, USA
J Am Soc Hypertens 5:230-8. 2011..Taken together, understanding racial (black-white) contrasts to stress contribute to both prevention and treatment of hypertension, especially for black males...
Prevention of type 2 diabetes mellitus to reduce cardiovascular morbidity and mortality: a review of the evidenceThomas D Giles
Heart and Vascular Institute, Tulane University School of Medicine, New Orleans, LA, USA
J Clin Hypertens (Greenwich) 11:512-9. 2009..A large ongoing study is investigating whether therapy with an oral antidiabetic drug or an angiotensin II receptor blocker reduces the incidence of new-onset diabetes and cardiovascular events in high-risk patients...
Effects of olmesartan medoxomil on systolic blood pressure and pulse pressure in the management of hypertensionThomas D Giles
Division of Cardiology, Louisiana State University School of Medicine, New Orleans 70112, USA
Am J Hypertens 17:690-5. 2004..In this analysis, we evaluated the efficacy of the angiotensin II receptor blocker olmesartan medoxomil in reducing systolic blood pressure (SBP) and pulse pressure (PP) in hypertensive patients...
The patient with diabetes mellitus and heart failure: at-risk issuesThomas D Giles
Section of Cardiovascular Research, Louisiana State University Health Science Center, New Orleans, Louisiana 70112, USA
Am J Med 115:107S-110S. 2003..Thus the risk-benefit ratio of using TZDs in patients who have diabetes and heart failure must be carefully considered in this patient population with comorbid disorders...
Applying the strategy of combination antihypertensive therapy to special populationsThomas D Giles
Section of Cardiology, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA
J Clin Hypertens (Greenwich) 8:2-3. 2006
Examining therapeutic goals: population versus individual-based approachesThomas D Giles
Department of Medicine, Louisiana State University School of Medicine, New Orleans, Louisiana 70112, USA
Am J Hypertens 16:26S-30S. 2003..Ultimately, the treatment decisions should be tailored to each patient, integrating as much information as possible concerning the patient's history, risk, pathophysiology, and lifestyle...
A perspective on telmisartan and cardiovascular riskThomas D Giles
Division of Cardiology, Department of Medicine, Tulane University School of Medicine, New Orleans, Louisiana, USA
Rev Cardiovasc Med 8:154-9. 2007....
Expanding the definition and classification of hypertensionThomas D Giles
Louisiana State University School of Medicine, New Orleans, LA 70112, USA
J Clin Hypertens (Greenwich) 7:505-12. 2005..We believe it would be preferable to classify all individuals as either normal or hypertensive, based on their cardiovascular evaluation, using the four categories of normal and stages 1, 2, and 3 hypertension...
Update on the management of diabetes and hypertensionThomas D Giles
Louisiana State University Medical Center, New Orleans, LA 70112, USA
J Clin Hypertens (Greenwich) 4:3-10. 2002
Relevance of blood pressure variation in the circadian onset of cardiovascular eventsThomas Giles
Louisiana State University Health Sciences Center, New Orleans, Louisiana 70112, USA
J Hypertens Suppl 23:S35-9. 2005..The technique has demonstrated, for example, a significantly greater reduction in blood pressure for the last 6 h of the 24-h dosing interval with telmisartan compared with valsartan...
Pioglitazone and heart failure: results from a controlled study in patients with type 2 diabetes mellitus and systolic dysfunctionThomas D Giles
Tulane University School of Medicine, New Orleans, Louisiana, USA
J Card Fail 14:445-52. 2008..We compared the effects of pioglitazone and glyburide on cardiac function in patients with type 2 diabetes, systolic dysfunction, and New York Heart Association (NYHA) functional Class II/III HF...
Medical management of myocardial ischemiaGary E Sander
Cardiovascular Research Laboratory, Louisiana State University Health Sciences Center, New Orleans, LA 70112-2825, USA
Am J Geriatr Cardiol 14:205-9. 2005
Rationale for combination therapy as initial treatment for hypertensionThomas D Giles
Louisiana State University School of Medicine, New Orleans, LA 70112, USA
J Clin Hypertens (Greenwich) 5:4-11. 2003....
Defining the antihypertensive properties of the angiotensin receptor blocker telmisartan by a practice-based clinical trialThomas D Giles
LSU School of Medicine, New Orleans, Louisiana, USA
Am J Hypertens 16:460-6. 2003....
ASH position paper: treatment of hypertension in patients with diabetes-an updateGeorge L Bakris
Hypertensive Diseases and Diabetes Center, Department of Medicine, University of Chicago Pritzker School of Medicine, Chicago, IL 60637, USA
J Clin Hypertens (Greenwich) 10:707-13; discussion 714-5. 2008..Last, an updated algorithm is provided that incorporates many of the new findings and is suggested as a starting point to achieve blood pressure goals...
The need for defining- and redefining- hypertension: beyond the numbersThomas D Giles
Cardiovascular Research, Louisiana State University School of Medicine, New Orleans, LA 70112, USA
Postgrad Med 118:21-5. 2005..In this article, Drs Giles and Sander review the current definitions of hypertension in clinical practice and its evaluation in light of total cardiovascular risk...
ALLHAT and ANBP2: what have we learned from recent mega-trials?Gary E Sander
Section of Cardiology, Department of Medicine, Louisiana State University Health Sciences Center, New Orleans, LA 70112 2825, USA
Am J Geriatr Cardiol 12:267-71. 2003
Pharmacologic update: treatment of erectile dysfunction in the elderly with phosphodiesterase type 5 inhibitors: cardiovascular implicationsPradeep Agarwal
Cardiovascular Research Laboratory, Louisiana State University Health Sciences Center, New Orleans 70112-2825, USA
Am J Geriatr Cardiol 13:332-5. 2004
HOPE in PROGRESS--a tale of two trials: blood pressure reduction or drug mechanism?Gary E Sander
Louisiana State University Health Sciences Center, New Orleans 70112, USA
Am J Geriatr Cardiol 11:332-3. 2002
The endocannabinoid system and cardiovascular risk: pathophysiologic role and developing therapeutic interventionsGary E Sander
Section of Cardiology, Department of Medicine, Tulane Medical Center, New Orleans, LA 70112, USA
Am J Geriatr Cardiol 15:255-9. 2006
Hypertension and lipids: lipid factors in the hypertension syndromeGary E Sander
Cardiovascular Research Laboratory, Louisiana State University Health Sciences Center, 1542 Tulane Avenue, New Orleans, LA 70112, USA
Curr Hypertens Rep 4:458-63. 2002..Recognition and identification of multiple risk factors and appropriate treatment in a manner that minimizes excessive oxidative stress is critical to the maintenance of normal endothelial cell function and cardiovascular risk reduction...
Renin-angiotensin system modulation for treatment and prevention of cardiovascular diseases: toward an optimal therapeutic strategyThomas D Giles
Division of Cardiology, Tulane University School of Medicine, New Orleans, Louisiana, USA
Rev Cardiovasc Med 8:S14-21. 2007..This article examines the results of clinical trials of ACE inhibitors and ARBs and assesses the potential for improving outcomes through a more global inhibition of the RAS with renin inhibitors...
Beta-blocker therapy for patients with ventricular heart failure and reduced systolic functionThomas D Giles
Division of Cardiology, Louisiana State University School of Medicine, New Orleans, LA 70112, USA
Postgrad Med 114:18-29. 2003..Other agents such as angiotensin II-receptor blockers and mineralocorticoid (aldosterone) receptor antagonists may also be important...
Pathophysiologic, diagnostic, and therapeutic aspects of the metabolic syndromeThomas D Giles
Section of Cardiology, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA
J Clin Hypertens (Greenwich) 7:669-78. 2005..Glucose-lowering agents may be indicated, and drugs such as metformin and thiazolidinediones, which reduce insulin resistance, should form the basis of therapy. Carefully chosen therapy will effectively improve cardiovascular outcomes...
The COMET trialMichael R Bristow
Division of Cardiology, University of Colorado Health Sciences Center, B130, Room 6430, 4200 East Ninth Avenue, Denver, CO 80262, USA
Congest Heart Fail 11:39-47. 2005
Use of beta-blockers for heart failure in patients with diabetes mellitusThomas D Giles
Cardiovascular Research Louisiana State University Health Science Center, 1542 Tulane Ave, Rm 331E, New Orleans, LA 70112, USA
Postgrad Med 112:32-7. 2002..These observations strongly support a role for the use of beta-blockers in patients with both heart failure and diabetes...
ASH Position Paper: Dietary approaches to lower blood pressureLawrence J Appel
Department of Medicine, Division of General Internal Medicine, Johns Hopkins University, Baltimore, MD 21205 2223, USA
J Clin Hypertens (Greenwich) 11:358-68. 2009..The current challenge is designing and implementing effective clinical and public health interventions that lead to sustained dietary changes among individuals and more broadly in the general population...
Noncardiac drugs and QTc interval prolongation: an often unrecognized risk factor for adverse cardiovascular outcomesGary E Sander
Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA
Am J Geriatr Cardiol 11:197-202. 2002
Diabetes mellitus and heart failure: basic mechanisms, clinical features, and therapeutic considerationsThomas D Giles
Section of Cardiology, Louisiana State University Health Sciences Center, 1542 Tulane Avenue, New Orleans, LA 70112, USA
Cardiol Clin 22:553-68. 2004..Such action will result in great benefit for patients by reducing morbidity and mortality and improving quality of life and will reduce the financial burden that is associated with this epidemic disease...
Alcohol--a cardiovascular drug?Thomas D Giles
Louisiana State University Health Services, New Orleans, LA 70112, USA
Am J Geriatr Cardiol 14:154-8. 2005
Ximelagatran: light at the end of the tunnel or the next tunnel?Gary E Sander
Section of Cardiology, Department of Medicine, Louisiana State University Health Sciences Center, New Orleans, LA 70112 2825, USA
Am J Geriatr Cardiol 13:221-4. 2004
Diabetes mellitus and heart failureGary E Sander
Section of Cardiology, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA
Am Heart Hosp J 1:273-80. 2003....
Statin therapy in the elderly-the evidence mountsGary E Sander
Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA
Am J Geriatr Cardiol 12:65-7. 2003
Adenoviral gene transfer of endothelial nitric-oxide synthase (eNOS) partially restores normal pulmonary arterial pressure in eNOS-deficient miceHunter C Champion
Department of Pharmacology, Tulane University Health Sciences Center, 1430 Tulane Avenue, New Orleans, LA 70112, USA
Proc Natl Acad Sci U S A 99:13248-53. 2002....
Beta-blockers for preventing sudden cardiac deathThomas D Giles
Division of Cardiovascular Research, Louisiana State University School of Medicine, New Orleans, LA 70112, USA
Postgrad Med 114:30-4. 2003..Clinical evidence reveals the association between beta-blockade and improved survival, and trials explore the role for beta-blockers in the prevention of sudden cardiac death...
Myocardial effects of ethanol consumption in the rat with streptozotocin-induced diabetesThomas D Giles
Section of Cardiology, Department of Medicine, Louisiana State University Health Sciences Center, 1542 Tulane Avenue, New Orleans, LA 70112, USA
Alcohol Clin Exp Res 26:1128-33. 2002..We studied the effect of low-dose ethanol consumption on cardiac function, geometry, and PKC isoforms in the rat with STZ-induced diabetes...
Hypertension and heart failure sine heart failure. The ACC/AHA guidelines: a misadventure in the lexicography of cardiomyopathy and heart failure, particularly for the hypertensiveThomas D Giles
Louisiana State University Medical Center, 1542 Tulane Avenue, Room 331E, New Orleans, LA 70112, USA
J Clin Hypertens (Greenwich) 5:280-1. 2003
Treating stage 2 hypertensionThomas D Giles
University of Miami School of Medicine, Miami, FL 3310, USA
J Clin Hypertens (Greenwich) 7:464-70. 2005..In this clinical review, hypertension experts utilize a case study to provide a paradigm for treating older patients with stage 2 hypertension...
The Editor's Roundtable: Endothelial dysfunction in cardiovascular diseaseVincent E Friedewald
Department of Internal Medicine, The University of Texas Medical School at Houston, Houston, Texas, USA
Am J Cardiol 102:418-23. 2008
Beta-blockers in the treatment of hypertension: new data, new directionsMichael A Weber
State University of New York, Downstate Medical College, 450 Clarkson Avenue, Brooklyn, NY 11023, USA
J Clin Hypertens (Greenwich) 10:234-8. 2008
Correlates of pulse pressure reduction during antihypertensive treatment (losartan or atenolol) in hypertensive patients with electrocardiographic left ventricular hypertrophy (the LIFE study)Eva Gerdts
Haukeland University Hospital, Bergen, Norway
Am J Cardiol 89:399-402. 2002....
Roundtable discussion: hypertension in children and adolescentsMarvin Moser
Department of Medicine/Cardiology, Yale University School of Medicine, New Haven, CT, USA
J Clin Hypertens (Greenwich) 7:24-30. 2005..Townsend, MD, of the Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA; and Marvin Moser, MD, of the Department of Medicine/Cardiology, Yale University School of Medicine, New Haven, CT...
Blood pressure--the better biomarker: delay in clinical applicationThomas D Giles
J Clin Hypertens (Greenwich) 9:918-20. 2007
Quality of life measured in a practice-based hypertension trial of an angiotensin receptor blockerMichael A Weber
State University of New York Downstate College of Medicine, Brooklyn, NY 11203, USA
J Clin Hypertens (Greenwich) 5:322-9. 2003..001 for each) with the increases in the GWBI scores. Controlling blood pressure appears to be an important element in improving subjective health perceptions of hypertensive patients...
Comparative antihypertensive efficacy of angiotensin receptor blocker-based treatment in African-American and white patientsGeorge L Bakris
Department of Preventive Medicine, Rush University Medical Center, Chicago, IL 60612, USA
J Clin Hypertens (Greenwich) 7:587-95; quiz 596-7. 2005..We conclude that an angiotensin receptor blocker as part of a BP-lowering strategy is effective in previously untreated African-American patients, although a higher proportion will require the use of a diuretic compared with Caucasians...
The kidney and cardiovascular risk--implications for management: a consensus statement from the European Society of HypertensionLuis Ruilope
Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain
Blood Press 16:72-9. 2007....
An effectiveness study comparing algorithm-based antihypertensive therapy with previous treatments using conventional and ambulatory blood pressure measurementsMichael A Weber
SUNY Downstate Medical School, Brooklyn, NY 11203, USA
J Clin Hypertens (Greenwich) 8:241-50; quiz 251-2. 2006..A treatment algorithm based on the angiotensin receptor blocker, telmisartan, was confirmed by the blinded end point of ABPM as an efficacious alternative to other antihypertensive regimens in clinical practice...
First-step use of fixed-dose combination treatment in stage 2 hypertensive patients: has the time come?Michael A Weber
SUNY Downstate College of Medicine, New York, New York, USA
J Clin Hypertens (Greenwich) 9:276-84. 2007
Hypertensive patients with reduced blood pressure still have hypertension: the role of the hypertension specialistThomas D Giles
J Clin Hypertens (Greenwich) 9:497-9. 2007
The editor's roundtable: revisiting the role of beta blockers in hypertensionWilliam C Roberts
Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, Texas, USA
Am J Cardiol 100:253-67. 2007
Clinicians treating hypertension need to mind their "P's" (precision) and "Q's"(quantitation): a lesson from left ventricular hypertrophy regression and atrial fibrillationThomas D Giles
J Clin Hypertens (Greenwich) 9:314-5. 2007
Blood pressure goals for hypertension guidelines: what is wrong with "optimal"?Thomas D Giles
J Clin Hypertens (Greenwich) 8:835-9. 2006
The cardiometabolic syndrome and calcium channel blocker combination drugsJames R Sowers
Diabetes Research Center, University of Missouri Columbia, Columbia, MO, USA
J Cardiometab Syndr 2:207-12. 2007..The authors maintained full control of the discussion and the resulting content of this article...
Prehypertension--what is it and should it be treated?Marvin Moser
J Clin Hypertens (Greenwich) 8:812-8. 2006
Where are we going? Beyond JNC 7Thomas D Giles
Prev Cardiol 10:222-7. 2007..Discussants included Suzanne Oparil, MD, University of Alabama at Birmingham, Birmingham, AL, and Thomas G. Pickering, MD, DPhil, Columbia Presbyterian Medical Center, New York, NY...
Inhibiting the renin-angiotensin system to prevent cardiovascular diseases: do we need a more comprehensive strategy?Michael A Weber
State University of New York Downstate Medical Center, Brooklyn, NY, USA
Rev Cardiovasc Med 7:45-54. 2006....
Introduction: new directions in hypertension: beyond JNC VIThomas D Giles
Am J Hypertens 16:25S. 2003
Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight lossPaul Poirier
Quebec Heart and Lung Institute, Sainte Foy, Canada
Arterioscler Thromb Vasc Biol 26:968-76. 2006..As a whole, overweight/obesity predispose or is associated with numerous cardiac complications such as coronary heart disease, heart failure, and sudden death through its impact on the cardiovascular system...
Atherosclerotic renal artery stenosis and renovascular hypertension: clinical diagnosis and indications for revascularizationEdmund Kenneth Kerut
Heart Clinic of Louisiana, Marrero, 70072, USA
J Clin Hypertens (Greenwich) 8:502-9. 2006..Intervention response is variable, but the ongoing Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL) trial, comparing medical therapy with and without stenting, should provide management guidance...
ACE inhibitors: over two decades of useDomenic A Sica
Virginia Commonwealth University, Richmond, VA, USA
J Clin Hypertens (Greenwich) 7:531-7. 2005..Dr. Henry R. Black of Rush University Medical Center, Chicago, IL; and Dr. Vito M. Campese of the University of Southern California, Los Angeles, CA...
Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HFPrakash C Deedwania
Department of Veterans Affairs Medical Center, Fresno, Calif, USA
Am Heart J 149:159-67. 2005....
Alcohol and the cardiovascular system research challenges and opportunitiesDiane L Lucas
Division of Metabolism and Health Effects, National Institute on Alcohol Abuse and Alcoholism/NIH, Bethesda, MD, USA
J Am Coll Cardiol 45:1916-24. 2005....
Hypertension: definitions and guidelinesJohn B Kostis
University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, New Brunswick, NJ 08903, USA
J Clin Hypertens (Greenwich) 7:538-9. 2005
Pay (adequately) for what works: the economic undervaluation of office and ambulatory blood pressure recordingsThomas D Giles
J Clin Hypertens (Greenwich) 10:257-9. 2008
Beta-blocker therapy in hypertension: a need to pause and reflectThomas D Giles
J Am Coll Cardiol 51:516-7; author reply 517-8. 2008
The ASCOT Trial--are beta-blockers still useful as antihypertensive medication?Marvin Moser
Yale University School of Medicine, New Haven, CT, USA
J Clin Hypertens (Greenwich) 8:723-8. 2006
Research Grants
- MODERATE ALCOHOL USE--CARDIOVASCULAR RISKS AND BENEFITSThomas Giles; Fiscal Year: 2001..The exacerbation or prevention of EIH will be related to drug effects on the cell-signaling pathway. This research can define the cell-signaling pathway in EIH and provide new and novel approaches to treating EIH. ..
